Challenges of phase 1 clinical trials evaluating immune checkpoint-targeted antibodies (Q38636711)

5 September 2017

title

Challenges of phase 1 clinical trials evaluating immune checkpoint-targeted antibodies (English)

1 reference

5 September 2017

main subject

phase I clinical trial

0 references

1

S Postel-Vinay

0 references

Jean-Charles Soria

5

J-C Soria

0 references

Aurélien Marabelle

6

A Marabelle

0 references

Sandrine Aspeslagh

2

S Aspeslagh

0 references

Caroline Robert

4

C Robert

0 references

Emilie Lanoy

3

E Lanoy

0 references

author name string

S Postel-Vinay

1

1 reference

5 September 2017

S Aspeslagh

2

1 reference

5 September 2017

J-C Soria

5

1 reference

5 September 2017

A Marabelle

6

1 reference

5 September 2017

publication date

16 November 2015

1 reference

5 September 2017

1 reference

5 September 2017

volume

27

1 reference

5 September 2017

issue

2

1 reference

5 September 2017

page(s)

214-224

1 reference

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

5 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV550

Ipilimumab plus dacarbazine for previously untreated metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV550

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV550

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV550

Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV550

Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV550

Prime time for immune-checkpoint targeted therapy at ASCO 2015

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV550

Nivolumab in previously untreated melanoma without BRAF mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV550

Pembrolizumab for the treatment of non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV550

Pembrolizumab versus Ipilimumab in Advanced Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV550

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV550

Nivolumab and ipilimumab versus ipilimumab in untreated melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV550

Nivolumab plus ipilimumab in advanced melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV550

Trial Watch: Immunostimulatory monoclonal antibodies in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV550

Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV550

Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV550

Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV550

Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV550

Intrapatient dose escalation of anti-CTLA-4 antibody in patients with metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV550

Phase I/II study of ipilimumab for patients with metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV550

Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV550

Phase I Study of Pembrolizumab (MK-3475; Anti-PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV550

Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV550

Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV550

MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV550

Management of immune-related adverse events and kinetics of response with ipilimumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV550

Review of immune-related adverse events in prostate cancer patients treated with ipilimumab: MD Anderson experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV550

Ipilimumab and its toxicities: a multidisciplinary approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV550

Towards new methods for the determination of dose limiting toxicities and the assessment of the recommended dose for further studies of molecularly targeted agents--dose-Limiting Toxicity and Toxicity Assessment Recommendation Group for Early Trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV550

Defining dose-limiting toxicity for phase 1 trials of molecularly targeted agents: results of a DLT-TARGETT international survey.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV550

Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV550

Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV550

Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV550

Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV550

Modified toxicity probability interval design: a safer and more reliable method than the 3 + 3 design for practical phase I trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV550

OX40 is a potent immune-stimulating target in late-stage cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV550

Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV550

Overall Survival and Long-Term Safety of Nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV550

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV550

Phase I trials in oncology: a new era has started.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV550

Evaluation of statistical designs in phase I expansion cohorts: the Dana-Farber/Harvard Cancer Center experience.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV550

Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV550

Prospective validation of a prognostic score to improve patient selection for oncology phase I trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV550

Prognostic factors in patients with advanced transitional cell carcinoma of the urothelial tract experiencing treatment failure with platinum-containing regimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV550

Prognostic factors that determine the long-term survival of patients with unresectable metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV550

CTLA-4 blockade with ipilimumab induces significant clinical benefit in a female with melanoma metastases to the CNS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV550

Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV550

Antibody pharmacokinetics and pharmacodynamics

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV550

Population pharmacokinetic and pharmacodynamic analysis of tremelimumab in patients with metastatic melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV550

Bispecific antibody platforms for cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV550

Ipilimumab-dependent cell-mediated cytotoxicity of regulatory T cells ex vivo by nonclassical monocytes in melanoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV550

Impact of immune complex size and glycosylation on IgG binding to human FcγRs

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV550

Fc-Receptor Interactions Regulate Both Cytotoxic and Immunomodulatory Therapeutic Antibody Effector Functions

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV550

Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV550

Developing a common language for tumor response to immunotherapy: immune-related response criteria using unidimensional measurements

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV550

Optimizing immune-related tumor response assessment: does reducing the number of lesions impact response assessment in melanoma patients treated with ipilimumab?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV550

Review: anti-CTLA-4 antibody ipilimumab: case studies of clinical response and immune-related adverse events

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV550

An abscopal response to radiation and ipilimumab in a patient with metastatic non-small cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV550

Immunologic correlates of the abscopal effect in a patient with melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV550

Hepatotoxicity with combination of vemurafenib and ipilimumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV550

Intratumoral immunization: a new paradigm for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV550

Phase I/II trial of tremelimumab in patients with metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV550

Efficacy and safety of retreatment with ipilimumab in patients with pretreated advanced melanoma who progressed after initially achieving disease control

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV550

21 January 2018

Identifiers

DOI

10.1093/ANNONC/MDV550

1 reference

5 September 2017

1 reference